Market Overview

UPDATE: Credit Suisse Upgrades Boston Scientific to Outperform on Improving Top-Line

Share:
Related BSX
Benzinga's Top Upgrades
Goldman Remains Constructive on MedTech, Sees 'New Opportunities' Amid Selloff
Medtronic Q1 Beats Estimates; Guidance Affirmed (Investor's Business Daily)

Credit Suisse upgraded Boston Scientific (NYSE: BSX) from Neutral to Outperform and raised the price target from $6.00 to $7.50.

Credit Suisse noted, ": We're upgrading BSX to Outperform from Neutral given increased visibility into meaningful top-line improvement. We forecast 4% WW CC growth for BSX in 2014 (4% CAGR 2013-17), a significant uptick relative to low-to-mid single digit declines 2010-13. We see the acceleration driven by key pipeline areas with Asthmatx, S-ICD, left atrial appendage closure, TAVI, renal denervation & DBS growing at a combined 57% CAGR 2013-17 to ~13% of BSX' 2017 sales (up from <1% currently)."

Boston Scientific closed at $6.32 on Monday.

Latest Ratings for BSX

DateFirmActionFromTo
Aug 2015Goldman SachsUpgradesNeutralBuy
Aug 2015Credit SuisseAssumesOutperform
Jul 2015Stifel NicolausMaintainsBuy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (BSX)

Get Benzinga's Newsletters